SPA
SLDB icon

Sherbrooke Park Advisers’s Solid Biosciences SLDB Stock Holding History

Sherbrooke Park Advisers’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,768
Closed -$63.1K – 906
2024
Q4 		$63.1K Sell
15,768
-18,516
-54% -$102K 0.02% 700
2024
Q3 		$239K Buy
+34,284
New +$278K 0.05% 673

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sherbrooke Park Advisers's SLDB Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Solid Biosciences (SLDB) in Q1 2025, closing a stake of 15,768 shares — an estimated $63.1K sold.

Sherbrooke Park Advisers first reported a position in SLDB in Q3 2024 and held it in 2 quarters. The position peaked at $239K in Q3 2024. 124 funds tracked by Wall St. Rank hold SLDB as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Solid Biosciences position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 15,768 Solid Biosciences shares in Q1 2025, an estimated $63.1K.
  • Sherbrooke Park Advisers first reported a position in Solid Biosciences in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Solid Biosciences position peaked at $239K in Q3 2024.
  • 124 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.